# A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

> **NCT03098797** · PHASE2,PHASE3 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 12 (actual)

## Conditions studied

- Barth Syndrome

## Interventions

- **DRUG:** Elamipretide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03098797
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-05
- **Primary completion:** 2018-10-05
- **Final completion:** 2021-10-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098797, "A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03098797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*